<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937105</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT00937105</nct_id>
  </id_info>
  <brief_title>Daily Wear Corneal Infiltrative Event Study</brief_title>
  <acronym>DWCIE</acronym>
  <official_title>Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This DWCIE Study is a prospective cohort study of patients fit to the FDA approved and
      marketed lotrafilcon A (Ciba Vision, Air Optix Night &amp; Day Aqua) soft contact lenses for
      daily wear (DW) with monthly disposal. 218 healthy myopic (nearsighted) or hyperopic
      (farsighted) patients with minimal or no astigmatism and no contraindications to DW lens use
      will be followed for 1 year. The primary outcome is the risk of development of a corneal
      inflammatory event (CIE) as defined by slit lamp findings and patient symptoms. The main
      exposure of interest is microbial contamination of study lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Developing a Corneal Inflammatory Event (CIE)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Raw number of participants in each solution arm developing CIE over 12 month follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CIE Stratified by Microbial Bioburden on Lenses</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Microbial bioburden on lenses was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora on lenses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CIE Based Stratified by Presence or Absence of Corneal Staining Induced by Solution Use.</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Presumed solution induced corneal staining was defined as diffuse punctate fluorescein staining of at least 15% surface area in at least 4 of 5 zones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CIE Stratified by Microbial Bioburden on Lens Cases</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Microbial bioburden within lens storage cases was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CIE Stratified by Overall Microbial Bioburden on Lid Margins</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Microbial bioburden on lid margins was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora on lids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CIE Stratified by CNS Microbial Bioburden on Lid Margins</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Microbial bioburden with coagulase negative staphylococci (CNS) on lid margins was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal CNS flora on lids</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Myopia</condition>
  <condition>Hyperopia</condition>
  <condition>Corneal Infiltrative Events</condition>
  <arm_group>
    <arm_group_label>ReNu Multiplus and lotrafilcon A lenses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ReNu Multiplus contact lens care solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Care solution and lotrafilcon A lenses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clear Care Contact Lens Care Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lotrafilcon A contact lenses</intervention_name>
    <description>FDA approved soft contact lenses</description>
    <arm_group_label>ReNu Multiplus and lotrafilcon A lenses</arm_group_label>
    <arm_group_label>Clear Care solution and lotrafilcon A lenses</arm_group_label>
    <other_name>Air Optix Night &amp; Day Aqua contact lenses</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renu Multiplus</intervention_name>
    <arm_group_label>ReNu Multiplus and lotrafilcon A lenses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clear Care</intervention_name>
    <arm_group_label>Clear Care solution and lotrafilcon A lenses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be at least 15 years old.

          2. The patient must be free of any anterior segment disorders.

          3. The patient must have a spectacle corrected spherical refractive error between +5.50 D
             and -11.00 D with less than or equal to 1.00 D refractive cylinder.

          4. The patient must be correctable to 20/25 or better with spectacles.

          5. Flat and steep corneal curvatures from Simulated Keratometry readings must be between
             39.00 and 48.00 D.

          6. Can be successfully fit with lotrafilcon A lenses at the enrollment visit.

        Exclusion Criteria

          1. The patient has worn rigid gas permeable lenses within the last 30 days or
             polymethylmethacrylate lenses within the last 3 months.

          2. The patient must not be a current successful daily wear user of lotrafilcon A lenses.
             They may have tried lotrafilcon A lenses in the past, but must not have successfully
             worn these lenses for daily wear within the last 12 months.

          3. The patient has an autoimmune disease (except for Hashimoto's Thyroiditis),
             immunocompromising disease, connective tissue disease, atopic dermatitis, insulin
             dependent diabetes, or any other systemic disease that in the investigator's opinion
             will affect ocular health.

          4. The patient is taking chronic systemic medications such as corticosteroids,
             antimetabolites, or non-steroidal anti-inflammatory agents or any other medication
             that in the investigator's opinion will affect ocular physiology or study
             participation.

          5. The patient has any ocular disease or condition such as aphakia, corneal dystrophies,
             corneal edema, external ocular infection, iritis, or had any anterior segment surgery.

          6. The patient is taking any ocular medications. If a patient was previously taking any
             ocular medications, the medications must have been discontinued at least 2 weeks prior
             to enrollment.

          7. The patient must have less than or equal to grade 2 on any of the slit lamp
             observations of: upper tarsal papilla, corneal staining, corneal neovascularization,
             conjunctival injection, and lid erythema or scales. Slit lamp findings higher than
             grade 2 bias the patient toward an adverse event and it may be difficult to detect
             true change related to contact lens use.

          8. The patient is pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loretta Szczotka-Flynn, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Szczotka-Flynn L, Jiang Y, Raghupathy S, Bielefeld RA, Garvey MT, Jacobs MR, Kern J, Debanne SM. Corneal inflammatory events with daily silicone hydrogel lens wear. Optom Vis Sci. 2014 Jan;91(1):3-12. doi: 10.1097/OPX.0000000000000105.</citation>
    <PMID>24240354</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <results_first_submitted>July 1, 2013</results_first_submitted>
  <results_first_submitted_qc>January 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2014</results_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Loretta Szczotka-Flynn</investigator_full_name>
    <investigator_title>OD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From November 2009 to February 2012, 218 participants were randomized at the University Hospitals Case Medical Center Eye Institute.</recruitment_details>
      <pre_assignment_details>Existing soft lens wearers or non contact lens wearers were recruited, no wash out period was required</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lotrafilcon A Lenses and Clear Care</title>
        </group>
        <group group_id="P2">
          <title>Lotrafilcon A Lenses and Renu Multiplus</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline measures refer to the entire cohort of 218 participants that were randomized, stratified by solution group</population>
      <group_list>
        <group group_id="B1">
          <title>Lotrafilcon A and Renu</title>
        </group>
        <group group_id="B2">
          <title>Lotrafilcon A and Clear Care</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.4" spread="11.3"/>
                    <measurement group_id="B2" value="34.9" spread="11.5"/>
                    <measurement group_id="B3" value="34.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Developing a Corneal Inflammatory Event (CIE)</title>
        <description>Raw number of participants in each solution arm developing CIE over 12 month follow-up period</description>
        <time_frame>up to 1 year</time_frame>
        <population>This primary analysis includes the cohort of all 218 randomized participants. The measured values stratify participants by solution group, however, the statistical analysis reports on the entire cohort (both solution groups) consistent with the primary aim of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon A Lenses and Renu</title>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon A Lenses and Clear Care</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing a Corneal Inflammatory Event (CIE)</title>
          <description>Raw number of participants in each solution arm developing CIE over 12 month follow-up period</description>
          <population>This primary analysis includes the cohort of all 218 randomized participants. The measured values stratify participants by solution group, however, the statistical analysis reports on the entire cohort (both solution groups) consistent with the primary aim of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="88.1" upper_limit="96.5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cumulative Unadjusted Probability of Remaining Infiltrate Free in entire Cohort</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative Probability of no-CIE</param_type>
            <param_value>92.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.6</ci_lower_limit>
            <ci_upper_limit>96.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CIE Stratified by Microbial Bioburden on Lenses</title>
        <description>Microbial bioburden on lenses was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora on lenses</description>
        <time_frame>up to 1 year</time_frame>
        <population>All participants in which valid lens bioburden data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Microbial Bioburden on Lenses</title>
          </group>
          <group group_id="O2">
            <title>Participants Without Microbial Bioburden on Lenses</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CIE Stratified by Microbial Bioburden on Lenses</title>
          <description>Microbial bioburden on lenses was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora on lenses</description>
          <population>All participants in which valid lens bioburden data was available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0.490" upper_limit="6.156"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To determine if microbial contamination of lenses is a risk factor for CIE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3923</p_value>
            <method>Regression, Cox</method>
            <method_desc>Univariate hazard ratio provided because non-significant finding did not enter into multivariate analyses</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.737</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>6.156</ci_upper_limit>
            <estimate_desc>referent is no substantial lens bioburden</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CIE Based Stratified by Presence or Absence of Corneal Staining Induced by Solution Use.</title>
        <description>Presumed solution induced corneal staining was defined as diffuse punctate fluorescein staining of at least 15% surface area in at least 4 of 5 zones</description>
        <time_frame>up to 1 year</time_frame>
        <population>Number of participants with valid presumed solution induced corneal staining data in each group</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Corneal Staining</title>
          </group>
          <group group_id="O2">
            <title>Participants Without Corneal Staining</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CIE Based Stratified by Presence or Absence of Corneal Staining Induced by Solution Use.</title>
          <description>Presumed solution induced corneal staining was defined as diffuse punctate fluorescein staining of at least 15% surface area in at least 4 of 5 zones</description>
          <population>Number of participants with valid presumed solution induced corneal staining data in each group</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.167" upper_limit="10.393"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7943</p_value>
            <method>Regression, Cox</method>
            <method_desc>Univariate hazard ratio provided because non-significant finding did not enter into multivariate analyses</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.316</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.167</ci_lower_limit>
            <ci_upper_limit>10.393</ci_upper_limit>
            <estimate_desc>referent is no corneal staining</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CIE Stratified by Microbial Bioburden on Lens Cases</title>
        <description>Microbial bioburden within lens storage cases was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora</description>
        <time_frame>up to 1 year</time_frame>
        <population>All participants in which valid lens case bioburden data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Microbial Bioburden on Lens Cases</title>
          </group>
          <group group_id="O2">
            <title>Participants With no Microbial Bioburden on Lens Cases</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CIE Stratified by Microbial Bioburden on Lens Cases</title>
          <description>Microbial bioburden within lens storage cases was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora</description>
          <population>All participants in which valid lens case bioburden data was available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0.161" upper_limit="2.822"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5894</p_value>
            <method>Regression, Cox</method>
            <method_desc>Univariate hazard ratio provided because non-significant finding did not enter into multivariate analyses</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.674</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>2.822</ci_upper_limit>
            <estimate_desc>referent is no substantial case bioburden</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CIE Stratified by Overall Microbial Bioburden on Lid Margins</title>
        <description>Microbial bioburden on lid margins was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora on lids</description>
        <time_frame>up to 1 year</time_frame>
        <population>All participants in which valid lens bioburden data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Microbial Bioburden on Lid Margins</title>
          </group>
          <group group_id="O2">
            <title>Participants With no Microbial Bioburden on Lid Margins</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CIE Stratified by Overall Microbial Bioburden on Lid Margins</title>
          <description>Microbial bioburden on lid margins was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal flora or presence of pathogenic abnormal flora on lids</description>
          <population>All participants in which valid lens bioburden data was available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1.10" upper_limit="24.70"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1742</p_value>
            <p_value_desc>Univariate hazard ratio provided because non-significant finding did not enter into multivariate analyses</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.406</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.678</ci_lower_limit>
            <ci_upper_limit>8.537</ci_upper_limit>
            <estimate_desc>referent is no substantial overall lid bioburden</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CIE Stratified by CNS Microbial Bioburden on Lid Margins</title>
        <description>Microbial bioburden with coagulase negative staphylococci (CNS) on lid margins was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal CNS flora on lids</description>
        <time_frame>up to 1 year</time_frame>
        <population>All participants in which valid lids bioburden data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With CNS Bioburden on Lid Margins</title>
          </group>
          <group group_id="O2">
            <title>Participants With no CNS Bioburden on Lid Margins</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CIE Stratified by CNS Microbial Bioburden on Lid Margins</title>
          <description>Microbial bioburden with coagulase negative staphylococci (CNS) on lid margins was determined with predetermined cutoffs to identify substantial bioburden as high levels of normal CNS flora on lids</description>
          <population>All participants in which valid lids bioburden data was available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Regression, Cox</method>
            <method_desc>Multivariate model adjusted for solution, gender and age</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>5.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>24.70</ci_upper_limit>
            <estimate_desc>referent is no substantial CNS lid bioburden</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year</time_frame>
      <desc>CIE definitions adopted from the standards as listed in the â€œInstitute for Eye Research/L.V. Prasad Eye Institute (IER/LVPEI) Guide To Corneal Infiltrative Conditions
Contact Lens Papillary Conjunctivitis was a clinical diagnosis that required temporary or permanent discontinuation of lens wear due to large papilla upon upper lid eversion</desc>
      <group_list>
        <group group_id="E1">
          <title>Entire Cohort of Lotrafilcon A Users</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>microbial keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>corneal infiltrative event</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Contact Lens Papillary Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Mostly asymptomatic CIE events occurred which limited the ability to retrieve the lens worn (for culture) precisely at the time of CIE development; this may have hindered our ability to capture bioburden at the time of the adverse event.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Loretta Szczotka-Flynn OD, PhD</name_or_title>
      <organization>University Hospitals Eye Institute</organization>
      <phone>216-844-3609</phone>
      <email>loretta.szczotka@uhhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

